open access

Vol 89, No 5 (2021)
Brief communication
Submitted: 2021-01-04
Accepted: 2021-05-14
Published online: 2021-09-24
Get Citation

Prediction of three-month readmission based on haematological parameters in patients with severe COPD exacerbation

Eduardo Garcia-Pachon1, Carlos Baeza-Martinez1, Sandra Ruiz-Alcaraz1, Justo Grau-Delgado1
DOI: 10.5603/ARM.a2021.0076
·
Pubmed: 34612507
·
Adv Respir Med 2021;89(5):501-504.
Affiliations
  1. Department of Respiratory Medicine, Hospital General Universitario de Elche, Elche, Alicante, Spain

open access

Vol 89, No 5 (2021)
BRIEF REPORT
Submitted: 2021-01-04
Accepted: 2021-05-14
Published online: 2021-09-24

Abstract

Introduction: Approximately one-third of patients hospitalised for an exacerbation of chronic obstructive pulmonary disease (COPD) are readmitted to the hospital within 90 days. It is of interest to identify biomarkers that predict relapse in order to prevent readmission in these patients. In our prospective study of patients admitted for COPD exacerbation, we aimed to analyse whether routine haematological parameters can help predict the three-month readmission risk.
Material and methods: 106 patients were included, of whom 23 were female (22%). The age (mean ± SD) was 73 ± 10 years, and the forced expiratory volume in 1 second (FEV1) was 44 ± 15%. The haematological parameters were obtained from the first blood test result during admission. The variables were as follows: red cell distribution width, mean platelet volume (MPV), platelet (PLT) count, neutrophil to lymphocyte ratio, PLT to lymphocyte ratio, MPV to PLT ratio, and eosinophil count. Patients were differentiated into two groups for each haematological parameter according to median value, and the percentage of readmissions in each of the groups was recorded.
Results: Twenty-five patients (24%) were readmitted to hospital within three months of discharge. Only the difference in low-MPV and high-MPV patients was significant (37% vs 10%, p = 0.001). The predictive capacity for three-month readmission measured by the area under the curve (AUC) did not show clinically applicable values; the best result was for MPV (AUC 0.64). In the remaining values, the AUC was between 0.52 and 0.55.
Conclusion: Routine haematological parameters proposed as prognostic biomarkers in COPD obtained at the moment of hospital admission were not useful for predicting three-month readmission.

Abstract

Introduction: Approximately one-third of patients hospitalised for an exacerbation of chronic obstructive pulmonary disease (COPD) are readmitted to the hospital within 90 days. It is of interest to identify biomarkers that predict relapse in order to prevent readmission in these patients. In our prospective study of patients admitted for COPD exacerbation, we aimed to analyse whether routine haematological parameters can help predict the three-month readmission risk.
Material and methods: 106 patients were included, of whom 23 were female (22%). The age (mean ± SD) was 73 ± 10 years, and the forced expiratory volume in 1 second (FEV1) was 44 ± 15%. The haematological parameters were obtained from the first blood test result during admission. The variables were as follows: red cell distribution width, mean platelet volume (MPV), platelet (PLT) count, neutrophil to lymphocyte ratio, PLT to lymphocyte ratio, MPV to PLT ratio, and eosinophil count. Patients were differentiated into two groups for each haematological parameter according to median value, and the percentage of readmissions in each of the groups was recorded.
Results: Twenty-five patients (24%) were readmitted to hospital within three months of discharge. Only the difference in low-MPV and high-MPV patients was significant (37% vs 10%, p = 0.001). The predictive capacity for three-month readmission measured by the area under the curve (AUC) did not show clinically applicable values; the best result was for MPV (AUC 0.64). In the remaining values, the AUC was between 0.52 and 0.55.
Conclusion: Routine haematological parameters proposed as prognostic biomarkers in COPD obtained at the moment of hospital admission were not useful for predicting three-month readmission.

Get Citation

Keywords

biomarkers; COPD; prognosis; readmission

About this article
Title

Prediction of three-month readmission based on haematological parameters in patients with severe COPD exacerbation

Journal

Advances in Respiratory Medicine

Issue

Vol 89, No 5 (2021)

Article type

Brief communication

Pages

501-504

Published online

2021-09-24

DOI

10.5603/ARM.a2021.0076

Pubmed

34612507

Bibliographic record

Adv Respir Med 2021;89(5):501-504.

Keywords

biomarkers
COPD
prognosis
readmission

Authors

Eduardo Garcia-Pachon
Carlos Baeza-Martinez
Sandra Ruiz-Alcaraz
Justo Grau-Delgado

References (13)
  1. Halpin DMg, Miravitlles M, Metzdorf N, et al. Impact and prevention of severe exacerbations of COPD: a review of the evidence. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2891–2908.
  2. Njoku CM, Alqahtani JS, Wimmer BC, et al. Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. Respir Med. 2020; 173: 105988.
  3. Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res. 2020; 6(2): 00325-2019.
  4. Hegelund A, Andersen IC, Andersen MN, et al. The impact of a personalised action plan delivered at discharge to patients with COPD on readmissions: a pilot study. Scand J Caring Sci. 2020; 34(4): 909–918.
  5. Adibi A, Sin D, Safari A, et al. The acute COPD exacerbation prediction tool (ACCEPT): a modelling study. Lancet Respir Med. 2020; 8(10): 1013–1021.
  6. Epstein D, Nasser R, Mashiach T, et al. Increased red cell distribution width: A novel predictor of adverse outcome in patients hospitalized due to acute exacerbation of chronic obstructive pulmonary disease. Respir Med. 2018; 136: 1–7.
  7. Ma Y, Zong D, Zhan Z, et al. Feasibility of mean platelet volume as a biomarker for chronic obstructive pulmonary disease: A systematic review and meta-analysis. J Int Med Res. 2019; 47(12): 5937–5949.
  8. Mallah H, Ball S, Sekhon J, et al. Platelets in chronic obstructive pulmonary disease: An update on pathophysiology and implications for antiplatelet therapy. Respir Med. 2020; 171: 106098.
  9. Paliogiannis P, Fois AG, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev. 2018; 27(147): 170113.
  10. El-Gazzar AG, Kamel MH, Elbahnasy OK, et al. Prognostic value of platelet and neutrophil to lymphocyte ratio in COPD patients. Expert Rev Respir Med. 2020; 14(1): 111–116.
  11. Couillard S, Larivée P, Courteau J, et al. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017; 151(2): 366–373.
  12. Xiong W, Xu M, Zhao Y, et al. Can we predict the prognosis of COPD with a routine blood test? Int J Chron Obstruct Pulmon Dis. 2017; 12: 615–625.
  13. Białas AJ, Pedone C, Piotrowski WJ, et al. Platelet distribution width as a prognostic factor in patients with COPD — pilot study. Int J Chron Obstruct Pulmon Dis. 2017; 12: 2261–2267.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Pneumonologia i Alergologia Polska dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl